Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy

NCT03959085 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.

NCT NCT03959085
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03959085 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
Lead sponsor
Children's Oncology Group
Phase
Phase 3
Overall status
Recruiting
Start date
October 31, 2019
Completion date
March 31, 2032
Enrollment
5,951 (estimated)
Sites
231

Conditions

As the registry lists them; a condition with its own page is linked.

b acute lymphoblastic leukemia, b lymphoblastic lymphoma, central nervous system leukemia, mixed phenotype acute leukemia, testicular leukemia